Effects of opioid, hypnotic and sedating medications on obstructive sleep apnoea (OSA) in adults with known OSA

Background

Obstructive sleep apnoea (OSA) is a common sleep disorder characterised by intermittent apnoeas (pauses in breathing) leading to dips in oxygen levels in the blood during sleep. Many people with known or unknown (undiagnosed) OSA receive hypnotics, sedatives and opiate/opioid drugs to treat other conditions including pain, anxiety and difficulty sleeping. Opiates/opioids are commonly prescribed to treat pain after major surgery. These drugs might make sleep apnoea worse - increasing the frequency and duration of apnoeas.

Review question

We set out to look at evidence derived from randomised placebo-controlled trials to identify the risks of these drugs for patients with known OSA.

What we did

We searched and reviewed all randomised placebo-controlled trials involving adult patients with known OSA who received these drugs. Most of the trials were short at just one or two nights' duration, involved only a small number of patients and used poorly described methodology. Therefore it was difficult to find out the exact effects of these drugs on patients with OSA.

Results

We found 14 studies examining the effects of 10 drugs in trials including 293 people.

Opiates and opioids (treatment of acute and chronic pain)

Remifentanil infusion

Remifentanil infusion did not significantly change severity of OSA as measured by numbers and duration of pauses in breathing during sleep, but it significantly lowered minimum oxygen levels during the night when compared with placebo.

Sedatives and hypnotics

'Z drugs' (a treatment for insomnia, inability to fall asleep or inability to maintain sleep)

Eszopiclone and zolpidem

Eszopiclone did not worsen OSA as measured by the numbers and duration of pauses in breathing during sleep. In one study, it reduced the severity of OSA, and it might be beneficial in treating this condition, although further studies are needed to assess this effect.

Zolpidem did not significantly worsen OSA as measured by the numbers and duration of pauses in breathing during sleep, but in one trial, it significantly lowered minimum oxygen levels during the night when compared with placebo.

Benzodiazepines (short-term relief of severe anxiety, behavioural disturbance or agitation and panic disorders)

Brotizolam, flurazepam, nitrazepam, temazepam and triazolam

None of the drugs examined had significantly worsened OSA as measured by the numbers and duration of pauses in breathing during sleep. In small, single-night studies, zolpidem 20 mg, flurazepam 20 mg and triazolam 0.25 mg showed a tendency to increase numbers and duration of pauses during sleep, which was not statistically significant, but these drugs significantly lowered minimum oxygen levels during the night when compared with placebo.

Sodium oxybate (a treatment for narcolepsy, a condition causing excessive sleepiness during the day)

Sodium oxybate was compared with placebo in two trials. Results showed that sodium oxybate did not worsen OSA as measured by the numbers and duration of pauses in breathing during sleep. In one study, sodium oxybate 4.5 g reduced the severity of OSA and might have proved beneficial in treating this condition, although further studies are needed to assess this effect.

Melatonin and melatonin-related drugs

Ramelteon (a treatment drug for insomnia)

Ramelteon was assessed in older adults, over 60 years of age, with OSA and insomnia and was found not to worsen OSA.

Results of this review show that the drugs studied do not worsen the severity of OSA as measured by the numbers and duration of pauses in breathing during sleep, but significant clinical and statistical decreases in minimum oxygen levels during the night were observed with remifentanil, zolpidem and triazolam; therefore prescribing these drugs for patients with OSA still warrants caution. Sodium oxybate 4.5 g and eszopiclone reduced the severity of OSA and might be beneficial in treating this condition; nonetheless further studies are needed to support these results.

Bottom line

The long-term effect and potential side effects of sedative drugs in people with OSA need to be assessed in larger, longer and methodologically robust studies.

Authors' conclusions: 

The findings of this review show that currently no evidence suggests that the pharmacological compounds assessed have a deleterious effect on the severity of OSA as measured by change in AHI or ODI. Significant clinical and statistical decreases in minimum overnight SpO2 were observed with remifentanil, zolpidem 20 mg and triazolam 0.25 mg. Eszopiclone 3 mg and sodium oxybate 4.5 g showed a beneficial effect on the severity of OSA with a reduction in AHI and may merit further assessment as a potential therapeutic option for a subgroup of patients with OSA. Only one trial assessed the effect of an opioid (remifentanil); some studies included CPAP treatment, whilst in a significant number of participants, previous treatment with CPAP was not stated and thus a residual treatment effect of CPAP could not be excluded. Most studies were small and of short duration, with indiscernible methodological quality.Caution is therefore required when such agents are prescribed for patients with OSA, especially outside the severity of the OSA cohorts and the corresponding dose of compounds given in the particular studies. Larger, longer trials involving patients across a broader spectrum of OSA severity are needed to clarify these results.

Read the full abstract...
Background: 

Obstructive sleep apnoea (OSA) is a common sleep disorder characterised by partial or complete upper airway occlusion during sleep, leading to intermittent cessation (apnoea) or reduction (hypopnoea) of airflow and dips in arterial oxygen saturation during sleep. Many patients with recognised and unrecognised OSA receive hypnotics, sedatives and opiates/opioids to treat conditions including pain, anxiety and difficulty sleeping. Concerns have been expressed that administration of these drugs to people with co-existing OSA may worsen OSA.

Objectives: 

To investigate whether administration of sedative and hypnotic drugs exacerbates the severity of OSA (as measured by the apnoea-hypopnoea index (AHI) or the 4% oxygen desaturation index (ODI)) in people with known OSA.

Search strategy: 

We searched the Cochrane Airways Group Specialised Register (CAGR) of trials. The search was current as of March 2015.

Selection criteria: 

Randomised, placebo-controlled trials including adult participants with confirmed OSA, where participants were randomly assigned to use opiates or opioids, sedatives, hypnotics or placebo. We included participants already using continuous positive airway pressure (CPAP) or a mandibular advancement device.

Data collection and analysis: 

We used standard methodological procedures as recommended by The Cochrane Collaboration.

Main results: 

Fourteen studies examining the effects of 10 drugs and including a total of 293 participants contributed to this review. Trials were small, with only two trials, which used sodium oxybate, recruiting more than 40 participants, and all but three trials were of only one to three nights in duration. Most participants had mild to moderate OSA with a mean AHI of 11 to 25 events/h, and only two trials recruited patients with severe OSA. Two trials investigating the effects of ramelteon, a treatment option for insomnia, recruited adults over 60 years of age with OSA and concomitant insomnia.

The drugs studied in this review included remifentanil (infusion) 0.75 mcg/kg/h, eszopiclone 3 mg, zolpidem 10 and 20 mg, brotizolam 0.25 mg, flurazepam 30 mg, nitrazepam 10 mg to 15 mg, temazepam 10 mg, triazolam 0.25 mg, ramelteon 8 mg and 16 mg and sodium oxybate 4.5 g and 9 g. We were unable to pool most of the data, with the exception of data for eszopiclone and ramelteon.

None of the drugs in this review produced a significant increase in AHI or ODI. Two trials have shown a beneficial effect on OSA. One study showed that a single administration of eszopiclone 3 mg significantly decreased AHI compared with placebo (24 ± 4 vs 31 ± 5; P value < 0.05), and a second study of sodium oxybate 4.5 g showed a significant decrease in AHI compared with placebo (mean difference (MD) -7.41, 95% confidence interval (CI) -14.17 to -0.65; N = 48).

Only four trials reported outcome data on ODI. No significant increase, in comparison with placebo, was shown with eszopiclone (21 (22 to 37) vs 28.0 (15 to 36); P value = NS), zolpidem (0.81 ± 0.29 vs 1.46 ± 0.53; P value = NS), flurazepam (18.6 ± 19 vs 19.6 ± 15.9; P value = NS) and temazepam (6.53 ± 9.4 vs 6.56 ± 8.3; P value = 0.98).

A significant decrease in minimum nocturnal peripheral capillary oxygen saturation (SpO2) was observed with zolpidem 20 mg (76.8 vs 85.2; P value = 0.002), flurazepam 30 mg (81.7 vs 85.2; P value = 0.002), remifentanil infusion (MD -7.00, 95% CI -11.95 to -2.05) and triazolam 0.25 mg in both rapid eye movement (REM) and non-REM (NREM) sleep (MD -14.00, 95% CI -21.84 to -6.16; MD -10.20, 95% CI -16.08 to -4.32, respectively.

One study investigated the effect of an opiate (remifentanil) on patients with moderate OSA. Remifentanil infusion did not significantly change AHI (MD 10.00, 95% CI -9.83 to 29.83); however it did significantly decrease the number of obstructive apnoeas (MD -9.00, 95% CI -17.40 to -0.60) and significantly increased the number of central apnoeas (MD 16.00, 95% CI -2.21 to 34.21). Similarly, although without significant effect on obstructive apnoeas, central apnoeas were increased in the sodium oxybate 9 g treatment group (MD 7.3 (18); P value = 0.005) in a cross-over trial.

Drugs studied in this review were generally well tolerated, apart from adverse events reported in 19 study participants prescribed remifentanil (n = 1), eszopiclone (n = 6), sodium oxybate (n = 9) or ramelteon (n = 3).

Share/Save